Compare FEIM & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | BNTC |
|---|---|---|
| Founded | 1961 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.4M | 405.7M |
| IPO Year | N/A | N/A |
| Metric | FEIM | BNTC |
|---|---|---|
| Price | $54.45 | $13.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $42.50 | $27.67 |
| AVG Volume (30 Days) | ★ 342.2K | 270.9K |
| Earning Date | 12-11-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.76 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $69,852,000.00 | N/A |
| Revenue This Year | $5.52 | N/A |
| Revenue Next Year | $17.07 | N/A |
| P/E Ratio | $24.86 | ★ N/A |
| Revenue Growth | ★ 16.06 | N/A |
| 52 Week Low | $13.69 | $9.70 |
| 52 Week High | $59.38 | $17.15 |
| Indicator | FEIM | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 76.37 | 54.43 |
| Support Level | $41.11 | $10.99 |
| Resistance Level | $58.27 | $13.36 |
| Average True Range (ATR) | 4.67 | 0.98 |
| MACD | 1.05 | 0.24 |
| Stochastic Oscillator | 81.99 | 79.04 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.